ARTBIO Therapeutics is a startup based in the United States, most recent round Series B, 1 tracked investor.
ARTBIO Therapeutics is a company founded in 2021 headquartered in the United States. Its most recent tracked round is Series B. Brouky records 1 investor associated with the company.
ARTBIO Therapeutics is a clinical-stage radiopharmaceutical company focused on developing a new class of alpha radioligand therapies (ARTs) for cancer treatment. The company utilizes lead-212 (Pb212), an optimal alpha-emitting isotope, combined with tumor-specific targets to create highly targeted therapies designed to improve patient outcomes.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.